MAIA Biotechnology Inc. (MAIA) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, MAIA Biotechnology Inc. (NYSE: MAIA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.10 (0.00% 1D, market cap $67.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MAIA ranks #724 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MAIA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TELO (Telomir Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and TENX (Tenax Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, MAIA leads on earnings multiple (N/A) while MAIA leads on capital efficiency (-35.0% ROIC).
Per MAIA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001878313), MAIA Biotechnology Inc. generated $68.0M in revenue (+43.1% YoY), -$22.4M in net income, and -$18.8M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 42.2 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While MAIA currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($1.16) forces dealer call-delta covering toward $3.35.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
MAIA Biotechnology Inc. (MAIA) slipped 0.00% to $1.10, trading at 10% of its 52-week range ($0.87 – $3.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Dealroom report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +43.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MAIA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MAIA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, MAIA Biotechnology Inc. (MAIA) ranks #724 by composite RQD confidence (32/100, grade E) and #698 by equity capitalization ($67.9M). Within this direct 5-issuer industry benchmark cohort, MAIA leads on earnings valuation at N/A trailing P/E, while MAIA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SDEV currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with MAIA at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MAIA
ACTIVE
MAIA Biotechnology Inc. | E | 32/100 | — | — | -35.0% | 0.00% | $67.9M | Benchmark Subject |
| TELO Telomir Pharmaceuticals Inc. | E | 28/100 | — | — | -35.0% | -2.15% | $67.4M | /telo-vs-maia → |
| TENX Tenax Therapeutics Inc. | E | 27/100 | — | — | -35.0% | +0.56% | $67.4M | /tenx-vs-maia → |
| SDEV Stablecoin Development Corporation | E | 33/100 | — | — | -35.0% | -8.91% | $67.3M | /sdev-vs-maia → |
| ACRV Acrivon Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -3.01% | $69.0M | /acrv-vs-maia → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), MAIA Biotechnology Inc. (MAIA) reported GAAP revenue of $68.0M (+43.1% vs. FY2024 revenue of $47.5M ) , GAAP net income of -$22.4M, operating cash flow of -$18.8M, and free cash flow of -$18.8M (-20.0% YoY). On the balance sheet, MAIA closed FY2025 with $9.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $68.0M | -$22.4M | -$18.8M | -$18.8M | $9.7M | — |
| FY2024 (FY) | 2024-12-31 | $47.5M | -$23.3M | -$15.7M | -$15.7M | $10.2M | — |
As of 2026-11-03, MAIA Biotechnology Inc. (NYSE: MAIA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.10 (0.00% 1D, market cap $67.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MAIA ranks #724 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MAIA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TELO (Telomir Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and TENX (Tenax Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, MAIA leads on earnings multiple (N/A) while MAIA leads on capital efficiency (-35.0% ROIC).
Per MAIA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001878313), MAIA Biotechnology Inc. generated $68.0M in revenue (+43.1% YoY), -$22.4M in net income, and -$18.8M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
MAIA last traded at $1.10 (0.00% on volume of 151,714 shares), positioning the stock -10.57% below its 50-day simple moving average ($1.23) and -24.14% below its 200-day simple moving average ($1.45). Across its 52-week range of $0.87 to $3.19, MAIA sits at the 9.9% percentile with a 14-day RSI of 42.2 (NEUTRAL RANGE) and an implied next-earnings move of ±10.4% ($1.00 to $1.21).
MAIA Biotechnology Inc. (MAIA) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.10 (0.00% 1D, market capitalization $67.9M).
MAIA Biotechnology Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $0.1B. Per the recent news wire, the company is advancing patient enrollment in Phase 2 and pivotal Phase 3 clinical trials in non-small cell lung cancer.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), MAIA Biotechnology Inc. (MAIA) reported $68.0M in annual revenue (up from $47.5M in FY2024, +43.1% YoY) and -$22.4M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($47.5M revenue, -$23.3M net income) through FY2025, MAIA scaled operating cash flow to -$18.8M and free cash flow to -$18.8M, backed by $9.7M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MAIA carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for MAIA Biotechnology Inc. (MAIA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Dealroom report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in MAIA in my $100K Virtual Cash book at $1.10. Enrollment milestones in Phase 2 and pivotal Phase 3 non-small cell lung cancer trials are the only cited near-term catalyst, and the stock trades 65% above its $0.87 52-week low.. Trading inside a $0.87–$3.19 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@DeltaGamma_99 Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.10 and keeping dry powder in case we test $1.02.
Fading this rally in MAIA at $1.10. With $0.0M reported revenue, ROIC of -35%, and 0% FCF yield, the RQD rating scores the company's cash engine at only 6 out of 20.. With a beta of 1.0 and the stock sitting at $1.10 (52-wk range $0.87–$3.19), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: